Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

Fentanyl

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

24 API Suppliers, 12 USDMF, 11 CEP/COS, 3 JDMF, 1 EU WC, 4 KDMF, 13 NDC API, 10 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

18 Drugs in Development

18 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

496 FDF Dossiers, 71 FDA Orange Book, 392 Europe, 5 Canada, 2 South Africa, 26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 4 DKSH, 2 Boai NKY Pharmaceuticals Ltd, 1 Nanjing Well Pharmaceutical, 1 Actylis, 1 Alcedo Pharmachem, 5 BASF, 1 Huzhou Sunflower Pharmaceutical, 1 Microlex e.U, 1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical, 6 Fillers, Diluents & Binders, 5 Direct Compression, 4 Thickeners and Stabilizers, 4 Rheology Modifiers, 3 Film Formers & Plasticizers, 2 Solubilizers, 2 Granulation, 1 Coating Systems & Additives, 1 Controlled & Modified Release, 1 Taste Masking

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 196 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 370 Regulatory FDF Prices, 21 Annual Reports

MARKET PLACE

5 APIs, 21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents, 5 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 6 USP, 11 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Name of the Firm	Written Confirmation No.	Product Name	Issue Date	Valid Till	Address of the Firm
12/09/2024	Rusan Pharma	India	M/s. Rusan Pharma Limited	WC-0278	Fentanyl EP/BP	2021-08-27	2024-06-10	Plot No. 6406, GIDC Estate, Ankleshwar-393002, Dist. Bharuch, Gujarat

Fentanyl

Fentanyl

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

24 API Suppliers

12 USDMF

11 CEP/COS

3 JDMF

1 EU WC

4 KDMF

13 NDC API

10 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

18 Drugs in Development

INTERMEDIATES

5 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

496 FDF Dossiers

71 FDA Orange Book

392 Europe

5 Canada

2 South Africa

26 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

4 DKSH

2 Boai NKY Pharmaceuticals Ltd

1 Nanjing Well Pharmaceutical

1 Actylis

1 Alcedo Pharmachem

5 BASF

1 Huzhou Sunflower Pharmaceutical

1 Microlex e.U

1 Novo Excipients

EXCIPIENTS BY APPLICATIONS

8 Topical

6 Fillers, Diluents & Binders

5 Direct Compression

4 Thickeners and Stabilizers

4 Rheology Modifiers

3 Film Formers & Plasticizers

2 Solubilizers

2 Granulation

1 Coating Systems & Additives

1 Controlled & Modified Release

1 Taste Masking

DIGITAL CONTENT

1 Data Compilation #PharmaFlow

196 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

370 Regulatory FDF Prices

21 Annual Reports

MARKET PLACE

5 APIs

21 FDF Dossiers

PATENTS & EXCLUSIVITIES

68 US Patents

5 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM

6 USP

11 Others

Filters

FILM, EXTENDED RELEASE;TRANSDERMAL - 100MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 12.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 25MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 37.5MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 50MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

FILM, EXTENDED RELEASE;TRANSDERMAL - 75MCG/HR Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons